AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00632645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
Study NCT00632645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenazine
Description: Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
Study NCT00632645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiapridal
Description: Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
Study NCT02075008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg/mL solution for subcutaneous injection
Study NCT03446209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab Infusion RoAcemtra (EU)
Description: Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
Study NCT03446209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Infusion RoAcemtra (EU)
Description: Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
Study NCT03446209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% physiological saline
Description: Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28.
Study NCT04053907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
Study NCT04053907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly fever screening and treatment
Description: Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
Study NCT04053907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly malaria screening
Description: CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
Study NCT04053907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDA
Description: CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
Study NCT01327092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Intervention Group
Description: The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
Study NCT03061578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Film Imager
Description: Ocular surface imaging assessment by the Tear Film Imager (TFI)
Study NCT03061578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low Humidity Environmental Exposure Chamber (LH-EEC)
Description: Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
Study NCT01155349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSight
Description: A cognitive intervention designed to enhance speed of visual processing.
Study NCT01155349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No contact-control group
Description: No contact-control group.
Study NCT03852186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Group based psychotherapy
Study NCT03852186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Group based psychotherapy
Study NCT00694356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study NCT05573438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group fructose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Study NCT05573438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Sucrose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Study NCT05573438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group Glucose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Study NCT04457401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
Study NCT04457401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains potato starch, magnesium stearate and ascorbic acid.
Study NCT00455221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcr-abl multipeptide vaccine
Description: The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
Study NCT00455221 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cytokine gene adjuvant
Description: Cytokine gene adjuvant
Study NCT00823953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Momordica charantia
Description: escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
Study NCT00823953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch powder
Description: The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
Study NCT02839005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture with polyglecaprone 25
Description: At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
Study NCT02839005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture with polyamide (nylon)
Description: At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
Study NCT00500968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: ERCP guided stent insertion before transection of the gland
Study NCT00500968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal pancreatectomy
Description: conventional distal pancreatectomy
Study NCT00675532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Counseling
Description: Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
Study NCT00675532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy
Description: Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
Study NCT02868840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: exercise twice a week each for one hour
Study NCT04024956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing Device
Description: The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
Study NCT03543956 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study NCT02811809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4 60mg tablets) daily
Study NCT02811809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHT
Description: Leuprolide 3-month depot 22.5 intramuscular dose
Study NCT02811809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IHT
Description: Leuprolide 3-month depot 22.5 intramuscular dose
Study NCT02471066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: * Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session
Study NCT02471066 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: * Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session
Study NCT03530956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Mimicking Prosthetic Foot prototype 4+
Description: The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
Study NCT03530956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Mimicking Prosthetic Foot prototype 4+
Description: The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
Study NCT01200472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
Study NCT01200472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical to apremilast
Study NCT02309749 — intervention group
Intervention type: OTHER
Intervention: CAP
Study NCT01781065 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT01781065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT00639925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1-1084, VEGFR2-169, and gemcitabine
Description: One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
Study NCT00588705 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus group & questionaire
Description: The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
Study NCT03090061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Light induced fluorescence intraoral camera
Description: assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
Study NCT03090061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual-tactile assessment method according to FDI criteria
Description: assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
Study NCT03692923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual community
Study NCT05091996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-isometric muscle relaxation technique
Description: 1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier.
Study NCT05091996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
Study NCT02702362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
Study NCT02702362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
Study NCT02923401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.
Study NCT02923401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
Study NCT02923401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
Study NCT02923401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Session
Description: One (1) time each month, participant attends a motivational session for 12 weeks.
Study NCT02923401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Session
Description: One (1) time each month, participant attends a motivational session for 12 weeks.
Study NCT02923401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
Study NCT02923401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed Materials
Description: High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist.
Study NCT04325165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Implantation
Description: Bilateral implantation of PPN DBS electrodes
Study NCT02103699 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
Study NCT03795285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of neutrophil CD64
Description: Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
Study NCT03635008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
Study NCT02868840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: symptom management
Description: sending text message weekly to manage symptoms related to stroke
Study NCT01028677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal spray with oxytocin
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
Study NCT03635008 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
Study NCT02112019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sialoendoscopy
Study NCT02112019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sialoendoscopy
Study NCT02112019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline